Previous studies have shown that targeted blockade of cachexia signaling with a novel HDAC inhibitor or a decoy receptor of ActRIIB prolonged survival while tumors continued to grow in animal models of cancer-induced cachexia [90, 91]. Here, ACVR2B is linked to cancer.